We use cookies and tracking technologies to offer you a better browsing experience, analyze site traffic, and improve the website. By clicking “Accept Cookies”, you expressly agree to our use of cookies and tracking technologies in accordance with our Cookie Policy. If you wish to prevent your data from being used by Google Analytics you can opt-out below.

Google Analytics Opt-Out
Our Network
Contact
Investors
Newsroom
Foundation
AmerisourceBergen logo
  • About Us
    • Who We Are
    • Our History
    • Our Stories
    • Our Leadership
    • Corporate Citizenship
    • Fighting the Opioid Epidemic
  • Solutions
    • Health Systems
    • Pharmacies
    • Physician Practices
    • Manufacturers
    • Animal Health
  • Insights
    • Insights Home
    • Explore Topics
  • Careers
    • Careers
    • Life at AmerisourceBergen
    • Search for Jobs
  • About Us
    • Who We Are
    • Our History
    • Our Stories
    • Our Leadership
    • Corporate Citizenship
    • Fighting the Opioid Epidemic
  • Solutions
    • Health Systems
    • Pharmacies
    • Physician Practices
    • Manufacturers
    • Animal Health
  • Insights
    • Insights Home
    • Explore Topics
  • Careers
    • Careers
    • Life at AmerisourceBergen
    • Search for Jobs
Our Network
Contact
Investors
Newsroom
Foundation

Explore Topics

All Topics

Orphan Drugs

5 Results

AmerisourceBergen

How to Navigate Cell and Gene Therapy Reimbursement: Part Two

Ana Stojanovska
June 2018

Manufacturers

How to Navigate Cell and Gene Therapy Reimbursement: Part One

Ana Stojanovska
June 2018

An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.

Manufacturers

Understanding the Rare Disease Journey

Inverted color AmerisourceBergen icon
AmerisourceBergen
February 2017

An interview with Matt George, patient advocate and survivor of paroxysmal nocturnal haemoglobinuria (PNH), a debilitating, rare and life-threatening disorder.

Manufacturers

Orphan Drugs: Five Ways to Prove Product Value

Amy Grogg
Amy Grogg
AmerisourceBergen
February 2017

Demonstrate the value of rare disease therapies with these five key ways to connect where patients, physicians and payers perceive the most value.

Manufacturers

Do's and Don'ts for Orphan Drug Support Programs

AmerisourceBergen icon
Nancy Pilcher
Lash Group
November 2016

The five components manufacturers shouldn't ignore when building orphan drug support programs.

Facebook
LinkedIn
Twitter
Contact Us
Terms and Conditions
Privacy Statement
Cookies Policy
Data Subject Request
Copyright ©2019 AmerisourceBergen Corporation. All Rights Reserved.